CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in ...

Other vaccines (such as Moderna) were excluded from analyses. The final older (12-17 years) study cohort comprised 872,936 ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Shares of Moderna Inc. MRNA shed 6.86% to $46.83 Friday, on what proved to be an all-around favorable trading session for the ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Shares of Moderna Inc. MRNA slipped 2.78% to $51.81 Wednesday, on what proved to be an all-around positive trading session ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

The mRNA vaccines, from Pfizer-BioNTech and Moderna, target the KP.2 variant of the virus, and the protein-based vaccine from Novavax targets JN.1, the parent strain of KP.2 and other FLiRT variants.